Natrox is a technology company.
NATROX® Wound Care delivers advanced solutions to aid wound healing, even in chronic, non-healing wounds, through innovative topical oxygen therapy technology.
Natrox has raised $38.0M across 2 funding rounds.
Natrox has raised $38.0M in total across 2 funding rounds.
NATROX Wound Care, developed by Inotec AMD Ltd., is a medical technology company specializing in advanced wound care solutions for chronic, hard-to-heal wounds.[1][2][3][6] Its flagship product, NATROX® O₂, is a portable, wearable device delivering continuous topical oxygen therapy 24/7 directly to wounds, promoting faster healing, reducing wound size by 73%, and improving patient quality of life.[1][3][5] The company also offers NATROX IQ®, an intuitive online platform for clinicians to manage caseloads with automated data capture, consistent wound measurements, remote assessments, and AI-powered analysis.[3][5] Serving patients, healthcare professionals, and systems burdened by chronic wounds—which drive increased GP visits, hospital admissions, and nurse visits—NATROX addresses a global issue affecting millions by leveraging oxygen's natural healing properties in clinical and home settings.[1][3][5] Growth momentum includes international expansion (e.g., South Korea in 2023, UK distribution), key hires like Chief Medical Officer Dr. Thomas Serena, production scaling to 16,000 units/week by 2024, and awards such as "Best Wearable Tech in Health Care" (2020) and MedTech50 ranking (2021).[3][4][6]
NATROX originated from the personal struggle of "Mel," who faced a hard-to-heal wound and, after consulting friends at the University of Cambridge, invented a topical oxygen therapy device with a small team.[1][4] This led to the formation of Inotec AMD Limited in Cambridge, UK, with a mission to develop innovative medical technology for chronic wound patients, ensuring "everyone deserves a chance to heal."[1][6] Early collaboration with Meridian Medical in 2011 refined the disposable components, evolving from initial RF tooling to CE-certified cleanroom production (MK2 tooling), enabling market entry and scaling amid surging demand in 2023.[4] Pivotal moments include clinical trials showing 71% greater healing rates, Federal Supply Schedule status for veterans, and leadership appointments like CEO Craig Kennedy (ex-MolecuLight CEO, Systagenix VP), who brought wound care expertise.[1][2][3][5]
NATROX rides the wave of advanced wound care medtech, targeting the massive burden of chronic wounds that inflate healthcare costs through more visits and admissions.[1][3][5] Timing aligns with rising demand for home-based, wearable therapies post-pandemic, enabling 24/7 treatment without lifestyle disruption and supporting telehealth amid clinician shortages.[3][5] Market forces like aging populations, diabetes-driven wounds, and biofilm challenges favor oxygen therapy's natural, non-invasive approach, with RCT data showing 71% better outcomes.[5][6] NATROX influences the ecosystem by integrating into global regimens (e.g., veterans' care, South Korea), partnering for distribution/production, and driving innovation via platforms like NATROX IQ®, which optimizes resources and outcomes across care continuums.[3][4][5]
NATROX is poised for accelerated global adoption as production scales and clinical evidence mounts, potentially becoming a standard in wound care protocols.[3][4][6] Trends like AI-enhanced telehealth, wearable medtech, and value-based care will amplify its edge, especially in high-burden areas like veterans' health and emerging markets.[5] Influence may evolve through further trials, acquisitions, or platform expansions, transforming chronic wound management from reactive to proactive—restoring hope, as its mission promises, for millions still seeking to heal.[1]
Natrox has raised $38.0M in total across 2 funding rounds.
Natrox's investors include 360 Capital Partners, Air Street Capital, Amadeus Capital Partners.
Natrox has raised $38.0M across 2 funding rounds. Most recently, it raised $33.0M Series C in December 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2024 | $33.0M Series C | 360 Capital Partners, Air Street Capital, Amadeus Capital Partners | |
| Mar 1, 2021 | $5.0M Series C |